Ronald Levy

This article is about the American oncologist. For the Jamaican hurdler, see Ronald Levy (athlete) .

Ronald Levy (born December 6, 1941 in Carmel-by-the-Sea ) is an American oncologist .

Levy studied at Harvard University (bachelor's degree in 1963) and Stanford University , where he earned his MD in 1968 . From 1968 he had an internship and then residency at the Massachusetts General Hospital . In 1970 he switched to the immunological department of the National Cancer Institute as a researcher and from 1972 he was again at Stanford University in the oncology department. In 1975 he became assistant professor there, 1981 associate professor, 1987 professor and from 1993 head of oncology at Stanford Medical School. He is currently Robert K. and Helen K. Summy Professor there.

From around 1980 Levy was the first to successfully treat malignant lymphomas with monoclonal antibodies . In this area, he was involved in the development of the cancer drug Rituxan , which was approved in the USA in 1997.

He won the Armand Hammer Award for Cancer Research in 1982, the Kanofsky Award from the American Society of Clinical Oncology in 1999 and the Dr. Josef Steiner Cancer Research Prize . In 1999 he received the Kettering Prize , the Medal of Honor from the American Cancer Society in 2000 and the König Faisal Prize in 2009 . In 2008 Levy was elected to the National Academy of Sciences .

Web links

• Biography on the occasion of the Kettering Prize 1999
• Laudation for the King Faisal Prize